Details of Integrative transcriptome analysis of prostate cancer with enzalutamide resistanc
Therapeutic resistance is a critical challenge in prostate cancer management. The lack of genome-wid...
Abstract Background Prostate cancer threatens the health of men over sixty years old, and its incide...
Microarrays have been used to identify genes involved in cancer progression. We have now developed a...
<p><b>Background:</b> Enzalutamide, a novel androgen receptor (AR) signaling inhibitor, has been wid...
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatment...
BackgroundMetastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the disease....
© 2021, The Author(s). Metastatic castration-resistant prostate cancer is typically lethal, exhibiti...
JunJie Yu,1,2 Si Sun,1,2 WeiPu Mao,1,2 Bin Xu,3 Ming Chen3– 5 1Surgical Research Center, Insti...
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with c...
Prostate cancer is the second leading cause of cancer death among men in the United States. The andr...
The development and diverse application of microarray and next generation sequencing technologies ha...
BACKGROUND: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumou...
An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year ...
Background: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumou...
Docetaxel has been proved to provide survival benefit for advanced prostate cancer (PCa) patients. R...
Therapeutic resistance is a critical challenge in prostate cancer management. The lack of genome-wid...
Abstract Background Prostate cancer threatens the health of men over sixty years old, and its incide...
Microarrays have been used to identify genes involved in cancer progression. We have now developed a...
<p><b>Background:</b> Enzalutamide, a novel androgen receptor (AR) signaling inhibitor, has been wid...
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatment...
BackgroundMetastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the disease....
© 2021, The Author(s). Metastatic castration-resistant prostate cancer is typically lethal, exhibiti...
JunJie Yu,1,2 Si Sun,1,2 WeiPu Mao,1,2 Bin Xu,3 Ming Chen3– 5 1Surgical Research Center, Insti...
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with c...
Prostate cancer is the second leading cause of cancer death among men in the United States. The andr...
The development and diverse application of microarray and next generation sequencing technologies ha...
BACKGROUND: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumou...
An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year ...
Background: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumou...
Docetaxel has been proved to provide survival benefit for advanced prostate cancer (PCa) patients. R...
Therapeutic resistance is a critical challenge in prostate cancer management. The lack of genome-wid...
Abstract Background Prostate cancer threatens the health of men over sixty years old, and its incide...
Microarrays have been used to identify genes involved in cancer progression. We have now developed a...
DOI
Add to ORKG